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Abstract (245) 70 
Background: Intrahepatic cholangiocarcinoma (ICC) is a significant public health problem in 71 
East Asia, where it is strongly associated with chronic infection by the food-borne parasite 72 
Opisthorchis viverrini (OV).  We report the first comprehensive miRNA expression profiling by 73 
microarray of the most common histologic grades and subtypes of ICC: well differentiated, 74 
moderately differentiated, and papillary ICC. 75 
Methods: MicroRNA expression profiles from FFPE were compared among the following: ICC 76 
tumor tissue (n = 16), non-tumor tissue distally macrodissected from the same ICC tumor block 77 
(n =15), and normal tissue (n =13) from individuals undergoing gastric bypass surgery. A panel 78 
of dysregulated miRNAs was validated by qPCR. 79 
Results: Each histologic grade and subtype of ICC displayed a distinct miRNA profile, with no 80 
cohort of miRNAs emerging as commonly dysregulated. Moderately differentiated ICC showed 81 
the greatest miRNA dysregulation in quantity and magnitude, followed by the papillary subtype, 82 
and then well differentiated ICC. Moreover, when ICC tumor tissues were compared to adjacent 83 
non-tumor tissue, similar miRNA dysregulation profiles were observed. 84 
Conclusions: We show that common histologic grades and subtypes of ICC have distinct 85 
miRNA profiles. As histological grade and subtypes are associated with ICC aggressiveness, 86 
these profiles could be used to enhance the early detection and improve the personalized 87 
treatment for ICC.  These findings also suggest the involvement of specific miRNAs during ICC 88 
tumor progression and differentiation. We plan to use these insights to (a) detected these 89 
profiles in circulation and (b) conduct functional analyses to decipher the roles of miRNAs in ICC 90 
tumor differentiation.  91 
 92 
93 
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INTRODUCTION 94 
Intrahepatic cholangiocarcinoma (ICC) is an adenocarcinoma which arises in the bile ducts 95 
within the liver [1] and is subcategorized morphologically as mass-forming, periductular-96 
infiltrating, or intraductal [2]. ICC is a serious public health problem in East Asia, especially in 97 
the Mekong River Basin countries of Thailand, Laos, Cambodia, and Vietnam [3-5], where the 98 
incidence of this tumor is the highest in the world (96 per 100,000) [3-5]. This is due to ICC’s 99 
strong association with chronic infection by the food-borne liver fluke Opisthorchis viverrini (OV) 100 
[6], one of three eukaryote pathogens considered Group 1 carcinogens by WHO’s International 101 
Agency for Research on Cancer [6]. Health disparities in this resource-poor region exacerbate 102 
mortality by OV-induced ICC because of either (a) suboptimal or nonexistent screening 103 
programs and (b) few resources for cancer treatment once a tumor is detected [7]. As OV-104 
induced ICC tends to present late, the prognosis is often poor, with a median survival rate of 105 
less than 24 months [8-10].  Hence, the urgent need for biomarkers for improved early detection 106 
of OV-induced CCA [11].  107 
Currently, tumor location and stage are the primary prognostic tools for ICC [8]. The WHO 108 
suggests a quantitative grading system for ICC tumor differentiation based on the proportion of 109 
gland formation [1]: well-differentiated tumors exhibit greater than 95% gland formation, 110 
moderately differentiated tumors exhibit between 50% to 95% gland formation, and poorly 111 
differentiated tumors exhibit between 5% to 49% gland formation. ICC can also undergo a 112 
secondary form of malignant transformation, as a papillary type adenocarcinoma [1]. Due to the 113 
late presentation of ICC and the need for re-sectioned liver sample, histology is seldom used in 114 
the prognosis or in the planning of patient treatment for ICC, even though moderately 115 
differentiated and papillary ICC are generally related to a poor outcome [11, 12].  As such, a 116 
biomarker in an accessible bodily fluid such as serum or urine, which could detect ICC prior to 117 
liver resection, would greatly aid current prognostic and planning methods for this cancer.  118 
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MicroRNAs (miRNAs) are key players in the control of numerous physiological and pathological 119 
processes during carcinogenesis, including cellular transformation, tumor differentiation, 120 
neoplastic proliferation, and apoptosis [13].  Altered expression of miRNAs has also been 121 
reported in other forms of hepatocellular carcinomas (HCC), where a strong correlation between 122 
miRNA dysregulation and histological differentiation of the tumor has been observed [14-17]. As 123 
miRNAs are well-preserved after formalin fixation, there has been a surge of interest in their 124 
development as biomarkers in retrospective cancer studies using FFPE as presented in the 125 
current manuscript [13].  126 
Although previous reports have focused on single miRNAs involved in the oncogenesis of OV-127 
induced ICC (e.g.,[16, 18-20]), this is the first study to comprehensively profile miRNA 128 
expression in tissue from the two most common histological grades of OV-induced ICC and 129 
single most common histological subtype of OV-induced ICC.  The miRNA expression profiles 130 
were established by microarray analysis on FFPE accessed from the tumor registry at the Liver 131 
Fluke and Cholangiocarcinoma Research Center, Khon Kaen, Thailand and the George 132 
Washington University (GWU) Medical Center using the following samples: (1) histologically 133 
confirmed intrahepatic cholangiocarcinoma tumor tissue (CTT); (2) histologically normal tissue 134 
distally macrodissected from the observed dysplasia or frank carcinoma from the same FFPE 135 
block as the CTT described above (Distal Normal Tissue or D-NT); and (3) histologically normal 136 
non-tumor tissue from individuals undergoing gastric bypass surgery (normal non-tumor tissue 137 
or N-NT). We hypothesize that miRNA dysregulation is associated not only with ICC, but also 138 
with the histological grade or the subtype of ICC and, may be informative for early diagnosis, 139 
prognosis, and patient planning for ICC.  140 
141 
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Materials and Methods 142 
Study Samples 143 
Formalin fixed paraffin embedded (FFPE) liver sections from histologically confirmed O. viverrini 144 
induced ICC archived at the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of 145 
Medicine, Khon Kaen University, Thailand were studied. The tumor samples and their 146 
corresponding distal non-tumor sections were derived from liver resections performed in the 147 
course of palliative treatment for confirmed cases of O. viverrini-associated ICC at the Khon 148 
Kaen University’s Srinagarind Hospital, Khon Kaen, Thailand. In addition, non-tumor controls 149 
were derived from livers of 13 individuals (N-NT) from biopsies taken prior to gastric bypass 150 
surgery at the George Washington University Medical Center (GWUMC), Washington D.C. to 151 
assess baseline liver histology in individuals suspected of severe steatosis or steatohepatitis. 152 
The 13 control individuals (N-NT) included 11 females and two males with an average age of 45 153 
years (95% Confidence Interval of 38 to 54 years of age). Clinico-pathological information and 154 
representative images of the tissues used in this study are presented in Table 1 and in Figure 1.  155 
Both the Khon Kaen University and GWU IRB determined that the samples used in this study 156 
did not meet the definition of human subjects research; i.e., a living individual about whom an 157 
investigator conducting research obtains: a) data through intervention or interaction with the 158 
individual or b) private identifiable information. This determination was made since the samples 159 
were limited to pre-existing, de-identified specimen analysis labeled with a random code.  160 
RNA isolation 161 
A master slide consisting of a 5µm section from the FFPE block was prepared and stained with 162 
Harris’s hematoxylin and eosin (H&E). Normal (D-NT), necrotic, and tumor tissue (CTT) regions 163 
were identified for each sample, and subsequently used as a template for additional microtome 164 
sections (8 x 5µm for each case). RNA was isolated from FFPE sections using the miRNeasy 165 
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FFPE kit (Qiagen) according to manufacturer’s protocol[21].  Total RNA was eluted in 30 µl 166 
RNase-free water. The concentration, purity and integrity of the RNA were determined by 167 
spectrophotometry (Nanodrop 1000) and with the Agilent 2100 Bioanalyzer/Agilent RNA 6000 168 
Nano Kit and Agilent Small RNA kit. Purified RNA was stored at -80°C. 169 
Microarray Analysis 170 
MicroRNA expression was profiled on the Agilent human miRNA microarray (miRBase Release 171 
16.0) between the following groups (1) ICC tumor tissue (CTT) (n = 16) and a corresponding 172 
non-tumor tissue distally macrodissected from the observed dysplasia or frank carcinoma from 173 
the same FFPE block from the same ICC tumor block (D-NT) (n = 15) (note case B91 did not 174 
contain corresponding non-tumor distal tissue); (2) CTT and normal non tumor-tissue (N-NT) (n 175 
= 13) from biopsies of individuals undergoing gastric bypass surgery at GWU; and (3) among 176 
the three common histological grades of OV-induced ICC: well differentiated (n = 6), moderately 177 
differentiated (n = 2), and papillary tumor (n = 8).  178 
Tissue from CTT, D-NT, and N-NT were equally distributed across six microarrays to prevent 179 
bias of the signals to a single microarray.  RNA was labeled with Cyanine 3-pCp using Agilent 180 
miRNA labeling and hybridization kits and hybridized to the Agilent human miRNA array and 181 
scanned. The feature intensities were transferred to digital data using Feature Extraction 182 
(V.10.7) software, along with hierarchical clustering [Agilent Gene Spring and Feature Extraction 183 
(V.10.7)] (Figure 2A). A sample of papillary tumor (a CTT sample) was excluded from analysis 184 
due to a low CC (correlation coefficient) value (<0.7). CC values of the other pairs ranged from 185 
0.7 to 1.  During analysis of these data, inter-sample variance was normalized using 90 186 
percentile normalization strategies. Hierarchical Clustering by Pearson correlation and 187 
Euclidean distance enabled clustering of samples with similar miRNA profiles, as well as 188 
enabling visualization of combinations of miRNAs with similar profiles across the different 189 
groups.  Differences among groups were statistically compared using one way Analysis of 190 
Variance (ANOVA), unpaired Student’s t-test, and fold change analysis with correction for 191 
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multiple testing (Benjamini & Hochberg or BH correction). P values of ≤0.05 were considered to 192 
be statically significant. 193 
Microarray data was prepared according to MIAME standards and deposited in the GEO (Gene 194 
Expression Omnibus Database, National Center for Biotechnology Information, U.S. National 195 
Library of Medicine, Bethesda, MD) under accession number GSE53992. 196 
Quantitative Reverse Transcription PCR (qPCR) 197 
cDNA was generated from 250 ng total RNA using the miScript RT II kit (Qiagen) according to 198 
the manufacturer’s protocol. qPCR was performed (in duplicate) using a Bio-Rad (Hercules, CA) 199 
iCycler iQ5 with miScript SYBR Green PCR Kit (Qiagen) with miScript Primer Assays (Qiagen) 200 
for controls and six selected miRNAs: miR--135b, -141, -200c, -21, -221, -222. Initial activation 201 
was completed at 95°C for 15 minutes followed by 40 cycles of denaturation, 15 sec, 94°C; 202 
annealing, 30 sec, 55°C; and extension, 30 sec, 70°C, followed by a melting curve analysis for 203 
81 cycles at 55°C and 20 sec dwell time. Ct values were exported and analyzed using 204 
SABiosciences tool (http://pcrdataanalysis.sabiosciences.com/mirna) and relative quantitation 205 
performed using the ∆∆Ct method [22].Normalization was accomplished using SNORD68 and 206 
SNORD95. 207 
RESULTS 208 
Cases and Controls   209 
Detailed clinicopathological characteristics of the ICC FFPE samples used in this study are 210 
shown in Table 1 and Figure 1. In brief, FFPE consisted of anonymously coded FFPE from 211 
histopathologically confirmed cases of ICC after informed consent from patients who underwent 212 
hepatectomy at Srinagarind Hospital, Khon Kaen University and were stored under Best 213 
Practices at the Liver Fluke and Cholangiocarcinoma Center, Khon Kaen University, Khon Kaen 214 
Thailand, where eligibility into this biorepository requires prior (positive sera or plasma) or 215 
current (fecal exam) evidence of infection with O. viverrini. The classification system used to 216 
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define the tumor growth characteristics of each sample in Table 1 were derived from The Liver 217 
Cancer Study Group of Japan [2]and identified tumors as [1] mass-forming, [2] periductal-218 
infiltrating, and [3] intraductal-growing types (Table 1). The Tumor Node and Metastasis (TNM) 219 
categories and the staging were derived from the American Joint Committee on Cancer Staging 220 
Manual (6th Edition) [23].  221 
Histological grading was done as described by the International Agency for Research on Cancer 222 
(IARC) [1]. In brief, assignment of well-differentiated adenocarcinoma to a tumor sample 223 
required that 95% of the tumor contain glands. For moderately differentiated, 40 to 94% of the 224 
tumor was composed of glands [1] (Figure 1). (Though neither poorly differentiated or 225 
undifferentiated carcinomas were used in this study, they would have to display between 5 to 226 
39% of the tumor containing glands or less than 5% of glandular structures, respectively [1].) In 227 
the case of papillary type ICC, we followed the IARC classification for tumors of the gallbladder 228 
and extrahepatic bile ducts [1], with the lesions having to consist predominantly of papillary 229 
structures lined by cells with a biliary phenotype, with good demarcation and consisting of 230 
papillary structures lined by tall columnar cells [1] (Figure 1).  231 
Purified RNA exhibited 260/280 and 260/230 Optical Density (OD) ratios of ~2.0 and ~1.9, 232 
respectively, indicating that it was pure, and suitable for downstream application. The Agilent 233 
2100 BioAnalyzer (data not shown) was utilized to evaluate the quality of purified RNA. RIN 234 
scores ranged from two to three for the samples and 28S and 18S ribosomal RNAs peaks were 235 
largely absent, together indicative of degradation of the RNA. RNA in FFPE is expected to be 236 
both modified and degraded due to the formalin and duration of storage [13, 24]. However, 237 
because of their small size, miRNAs are more stable than other RNA species and have reliably 238 
been purified from FFPE [13, 24]. Given the stability of miRNAs in FFPE tissue [25]and reports 239 
from other groups and us [26]that low RIN scores have negligible effect on miRNA profiles, the 240 
RNA was considered suitable for further analysis.   241 
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Tumors and corresponding distal non-tumor tissue shared distinct miRNA profiles 242 
Hierarchical clustering revealed that the N-NT samples grouped together (red tree lines), while 243 
clusters of D-NT (blue) and clusters of CTT (grey) scattered together across the heat map 244 
(Figure 2A). This observation was statistically confirmed by ANOVA analyses, which showed 245 
that there were fewer differences between the CTT and D-NT than between D-NT and N-NT, 246 
indicating that non-tumor tissue adjacent to ICC tumors shared similar miRNA profiles. The 3D 247 
Principal Components Analyses (Figure 2B) showed that N-NT samples clustered in a manner 248 
distinct from both CTT and their corresponding D-NT samples. 249 
One-way analysis of variance (ANOVA), and Student’s t-test were also used to compare and 250 
identify miRNAs significantly dysregulated among the three histological grades of OV-induced 251 
ICC: [1] well differentiated; [2] moderately differentiated, and [3] papillary ICC [1].  The first 252 
analysis compared CTT with corresponding D-NT from the same ICC FFPE block (Figure 3A), 253 
with a second comparison undertaken between CTT and N-NT (Figure 3B).  Each histological 254 
subtype of ICC showed a distinct suite of miRNAs, which they shared with the cognate distal 255 
non-tumor tissue (Figure 3A): i.e., tissue graded as well differentiated, moderately differentiated, 256 
or papillary ICC had discrete miRNA profiles, as did adjacent non-tumor tissue. There were, 257 
however, minor overlaps between the histological grades, with eight significantly dysregulated 258 
among well differentiated and papillary (hsa-miR-200c-3p, -141-3p, -429, -200a-3p, 200b-3p, -259 
222-3p, -210, and ebv-miR-BART1-5p). Additionally, four significantly dysregulated miRNAs 260 
were shared by papillary and moderately differentiated ICC (hsa-miR-122-3p, -122-5p, -885-5p, 261 
and -196b-5p).   262 
To determine if a distinctive profile of miRNAs could identify ICC tumor tissue from non-tumor 263 
liver tissue, the CTT samples as a single group (not divided by histological grade) were 264 
compared with the N-NT samples (liver tissue from individuals undergoing gastric bypass 265 
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surgery).  Here, 40 miRNAs were dysregulated when ICC tissues were compared to non-cancer 266 
liver tissue (Figure 3B). However, of these 40 dysregulated miRNAs, only six were shared 267 
among the ICC tumor samples when these ICC samples were grouped by histological grade. 268 
These six shared dysregulated miRNAs were used for qPCR validation of the microarray 269 
analysis. Notably, the remaining 34 dysregulated miRNAs fell into distinct profiles that were 270 
associated with the three histological grades of OV-induced ICC.  Hence, in a pattern seen 271 
throughout this study, the strongest and universal associations between miRNA dysregulation 272 
and ICC tumor were evident among the distinct profiles of dysregulated miRNAs and their 273 
association with ICC histological subtype. 274 
Distinct miRNA profiles strongly associated with the histologic grade and subtype of ICC  275 
We also compared CTT miRNA dysregulation without comparison to either histologically normal 276 
tissue (N-NT) or corresponding non-tumor distal tissue (D-NT). Sixty-one of the >1,600 miRNAs 277 
screened had a p value ≤ 0.05 and a fold change > 2.0 (Table 2). Further investigation revealed 278 
that miRNA dysregulation was again unevenly distributed among the histological subtypes, with 279 
the kind, quantity and the magnitude of the miRNA dysregulation strongly associated with the 280 
histological grade or subtype of the ICC. More specifically, miRNAs were significantly increased 281 
in the quantity and the magnitude of their dysregulation in moderately differentiated ICC 282 
compared to papillary ICC.  A similar increase in number and magnitude of dysregulated 283 
miRNAs were observed when papillary ICC was compared to well differentiated ICC (Table 2). 284 
In short, well-differentiated ICC showed the lowest miRNA dysregulation among the three 285 
histological grades, which likely reflects the phenomenon that, unlike papillary and moderately 286 
differentiated ICC, well-differentiated tumors show minimal cytological change and often closely 287 
resemble the bile duct tissue from which they arise.  288 
qPCR validated microarray findings 289 
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To confirm the microarray findings, we used qPCR to analyze six dysregulated miRNAs (above) 290 
shared among tumor tissue (CTT) when compared to normal tissue (N-NT): i.e., hsa-mir-135b, -291 
141, -200c, -21, -221, -222.  Dysregulation of expression of these six miRNAs was confirmed by 292 
qPCR; for example, when tumor tissue was analyzed against normal tissue (N-NT) (Figure 4), 293 
miR-141 showed the highest FC in both qPCR (FC = 371; p = 0.0007) and in the microarray. 294 
However, interestingly, the qPCR analysis confirmed the two outstanding trends determined by 295 
the microarray profiling (Figure 4 and Supplemental Figure 1). First, the magnitude of miRNA 296 
dysregulation was associated with histological subtype (Figure 4 and Supplemental Figure 1), 297 
with moderately differentiated tissue exhibiting the highest FC by qPCR for five of the six 298 
miRNAs (the exception was miR-21).  Second, distal tissue non-tumor tissue (D-NT) again 299 
closely resembled proximal tumor (CTT) in the magnitude of miRNA dysregulation (Data not 300 
shown).  301 
DISCUSSION 302 
This manuscript represents the first comprehensive miRNA expression profiling of OV-induced 303 
ICC by histological grades and subtype, adding to a growing literature on the role of miRNAs in 304 
hepatocellular neoplasms [14, 17, 20].  In the current report, RNA was recovered from FFPE 305 
[21] and used to screen Agilent miRNA microarrays and, for the first time, miRNA dysregulation 306 
has been shown to differentiate between healthy non-tumor liver tissue (N-NT) and three most 307 
common histopathological types of OV-induced ICC [1]: well-differentiated, moderately 308 
differentiated, and papillary ICC tumor. No shared profile of miRNAs emerged as commonly 309 
dysregulated among these common histologic subtypes and grade of OV-induced ICC.  In a 310 
repeated pattern, moderately differentiated ICC tissue showed both the greatest number and 311 
magnitude of miRNA dysregulation, followed by the papillary type of ICC, and then well-312 
differentiated ICC.  This trend likely reflects the fact that, by definition, moderately differentiated 313 
tumor tissue shows greater cytological changes and has the least resemblance to the bile duct 314 
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tissue from which the tumor arose. Moreover, the three histological subtypes of OV-induced ICC 315 
exhibited distinct miRNA signatures, suggestive of the involvement of specific sets of miRNAs in 316 
progression of this tumor.  This observation is consistent with findings for HCC [14, 17], where 317 
the type, number and magnitude of miRNA dysregulation increase with increasing histological 318 
differentiation.  Functional studies suggest that the association between miRNA dysregulation 319 
and histological subtype derive from miRNA modulation of key cellular processes involved in 320 
HCC tumor differentiation [14, 17].  321 
Unexpectedly, there was a close similarity in miRNA profiles between tumor tissues (CTT) and 322 
adjacent non-tumor (D-NT) tissue macrodissected distant from observed dysplasia or frank 323 
carcinoma in the FFPE.  These findings confirm our previous findings on ICC [27] where, even 324 
in the absence of obvious tumor mass or a differentiation in tissue morphology, genetic changes 325 
in nearby non-tumor tissue had already occurred.  This is also consistent with the role of 326 
miRNAs as messengers of tumor-cell invasion as recently described for breast cancer, where 327 
miRNAs and proteins involved in cancer progression were identified in exosomes isolated from 328 
breast cancer cell clines [25].  329 
When tumor tissues (CTT) were compared to healthy tissue (N-NT), 40 miRNAs were observed 330 
to be dysregulated.  However, the miRNAs dysregulation in this comparison may reflect the 331 
possible differences in the composition of the samples; CTT were biopsied from livers resected 332 
to confirm OV-induced ICC and may be enriched for cholangiocytes compared to hepatocytes. 333 
In comparison, N-NT were biopsied from individuals preparing to undergo gastric bypass 334 
surgery may contain more hepatocytes than cholangiocytes.  However, even against this 335 
backdrop of miRNA dysregulation possibly attributable to differences in the tissue composition 336 
and even ethnicity, [14, 17], the same pattern of miRNA dysregulation was evident: moderately 337 
differentiated ICC tissue showed the greatest miRNA dysregulation, followed by the papillary 338 
type of ICC tumor, and then well-differentiated ICC tumor tissue.  339 
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Only six miRNAs were commonly dysregulated among the three types of ICC when compared 340 
to healthy liver tissue by microarray, which we confirmed by qPCR. Moreover, the similarity 341 
between tumor tissue and their corresponding non-tumor tissue was also observed for these six 342 
miRNAs and validated by qPCR, confirming the possibility of genetic or miRNA alterations in 343 
apparently healthy tissue adjacent to dysplastic tissue or frank cancer.  Together, these data 344 
strongly support the main finding that miRNA dysregulation strongly associates with the 345 
histological subtypes of OV-induced ICC and is reflected in nearby non-tumor tissue.  346 
A large number of miRNAs have now been associated with different cancers and the majority of 347 
miRNAs identified in this work have been previously associated with cancer. For example, hsa-348 
mir-429 is upregulated in bladder cancer [28] and mirs 200c-3p, 141-3p, 200a-3p, 200b-3p have 349 
been identified with gastric esophageal [29], , bladder [28] and breast [30]cancer respectively. 350 
Two miRNAs typically associated with liver pathology, miR-885-5p [31] and mir-551b-5p [32] 351 
were also significantly dysregulated in ICC tissue versus controls, but also showed clear 352 
expression differences in the different grades of tumour. Few miRNAs associated with ICC in 353 
this study have not been previously been associated with cancer, but the few that have not, for 354 
example miR-593-3p, are therefore potential miRNA markers with specificity for ICC. 355 
The main limitation of this study is the absence of a set of non-malignant cholangiocyte tissues 356 
as controls, which are rare. If available, inclusion of normal cholangiocytes would provide a 357 
precise baseline for the progression of altered miRNA expression and deliver a more 358 
parsimonious miRNA profile associated with ICC subtype. Moreover, as we plan to detect these 359 
dysregulated profiles in bodily fluids the need for comparison to cholangiocytes will be reduced.  360 
The study also does not also contain functional analyses on the individual miRNAs found to be 361 
dysregulated.  However, the focus of the study was a comprehensive profiling of dysregulated 362 
miRNAs in ICC tumor tissue by histological grade. Such descriptive studies are integral 363 
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precursors to qualified, hypothesis-driven studies and can guide future functional studies in OV-364 
induced ICC.  365 
There are important translational implications arising from the findings.  As recently noted by 366 
Rizvi and Gores [33], ICC poses unique diagnostic and prognostic challenges due to its 367 
“paucicellular nature, anatomic location, and silent clinical character”, requiring a “high index of 368 
suspicion” and a “multidisciplinary approach” to diagnosis that involves clinical, laboratory, 369 
endoscopic, and radiographic analyses.  We add to this multidisciplinary approach miRNA-370 
profiling indicative of histopathological grade.  As the aggressiveness of ICC has been strongly 371 
associated with the degree of histological differentiation [34], miRNAs indicative of histological 372 
differential that are easily accessible in bodily fluids may increase their role in this 373 
multidisciplinary approach for ICC as they can be detected earlier and limit the invasive 374 
procedures referred to above. Currently, as ICC presents late during the disease, confirmatory 375 
needle aspiration biopsy or liver resection (hepatectomy) is required for the type of sample 376 
analyzed in this manuscript. However, if these dysregulated miRNAs could be detected in an 377 
accessible biofluid(s) (e.g., plasma, sera, urine, etc.) in persons with “a high index of suspicion” 378 
prior to liver resection, our findings offer an opportunity for early determination of type of ICC, 379 
which could aid in proper treatment.  As ICC is highly vascularized, with a propensity for 380 
angiogenesis, there is a good probability that these dysregulated miRNAs circulate in the blood. 381 
Hence, our ultimate objective is to target these dysregulated miRNA profiles in plasma or sera 382 
for screening.  Additionally, recent finding of circulating exosomes (or micro vesicles) “laden” 383 
with miRNAs secreted from the bile duct of individuals with ICC offers intriguing possibilities for 384 
miRNA trafficking and may be responsible for our observation of similarly dysregulated miRNA 385 
profiles in apparently normal tissue distal (D-NT) to paired tumors [35].  We plan to investigate 386 
miRNAs circulating in bodily fluids as well as their trafficking by exosomes in future studies.  In 387 
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addition, we also plan to explore the presence of novel miRNAs (not in miBAse 16) by 388 
untargeted profiling of these same ICC tissues by RNA Seq.  389 
Finally, as we were able to detect sets of dysregulated miRNAs associated with different CCA 390 
subtypes of ICC, we plan to perform functional analyses to decipher the roles of these particular 391 
miRNAs in the process of tumor differentiation, including both overexpression and knock-down 392 
experiments mediated by antagomirs and/or miRNA sponges [36]. The effect of these genetic 393 
manipulations would be evaluated at the phenotypic level, i.e. proliferation, migration assays, 394 
etc., and also at the gene expression level [19]. These approaches could advance our 395 
understanding in miRNAs in CCA oncogenesis and tumor biology, and advance therapeutic 396 
strategies for this infection-related cancer. 397 
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 513 
TABLES 514 
 
Table 1. Clinicopathological characteristics of 16 O. viverrini associated ICC patients used in study. 
ID Sex Age 
OV 
Status Ethnicity 
Histological 
grade 
Gross  
Classification TNM Staging 
B070 M 61 Positive Asian WD Mass-forming T3N0M0 IIIA 
B079 M 61 Positive Asian WD Periductal infiltrating, invasive intraductal and mixed T4N1M0 IIIB 
B083 F 53 Positive Asian WD Mass-forming T3N0M0 IIIA 
B099 M 48 Positive Asian WD Mass-forming T3N0M0 IIIA 
Y042 M 61 Positive Asian WD Mass-forming T3N1M0 IIIC 
B091 M 63 Positive Asian MD Periductal infiltrating, invasive intraductal and mixed T4N1M0 IIIB 
Y070 F 63 Positive Asian MD Mass forming T3N0M0 IIIA 
Y056 F 56 Positive Asian PC Periductal infiltrating, invasive intraductal and mixed T4N1M0 IIIB 
Y062 M 57 Positive Asian PC Periductal infiltrating, invasive intraductal and mixed T4N1M0 IIIB 
B049 M 64 Positive Asian PC Mass forming T3N0M0 IIIA 
Y083 F 51 Positive Asian PC Mass forming T3N1M0 IIIC 
Y088 F 58 Positive Asian PC Periductal infiltrating, invasive intraductal and mixed T4N1M0 IIIB 
Y089 F 60 Positive Asian PC Mass forming T3N1M0 IIIC 
Y093 M 63 Positive Asian PC Periductal infiltrating, invasive intraductal and mixed T4N1M0 IIIB 
Y096 F 64 Positive Asian PC Mass forming T3N1M0 IIIC 
M = Male; F  = Female 
Histological types: tumor differentiation: WD = Well Differentiated tubular adenocarcinoma; MD = Moderately Differentiated tubular 
adenocarcinoma; and PC = Papillary Carcinoma 
Staging: Tumor Node Modular Classification and Staging from AJCC Sixth edition [23] 
 515 
  
 24 
 
Table 2. Statistically significant miRNAs by ANOVA among histological grades 
of ICC. p(corr) < 0.05, FC > 2 in at least two conditions, and raw values >30. FC 
over 5 is highlighted gray.  
 
Fold Change 
miRNA p (Corr) 
Moderate vs. 
Papillary 
Moderate vs. 
Well 
Papillary vs. 
Well 
hsv1-miR-H5-5p 0.012487 -2.63889 2.5606 6.75720 
hsa-miR-122-3p 0.015622 -101.23811 -29.61597 3.41836 
hsa-miR-885-5p 0.029224 -25.07646 -9.7333 2.57634 
hsa-miR-122-5p 0.012487 -24.25102 -9.4541 2.56512 
hsa-miR-593-3p 1.29E-04 -3.28851 -1.321101 2.48921 
hsa-miR-3150b-3p 6.26E-04 -2.29151 -1.12618 2.03474 
hsa-miR-3615 0.01371 -3.34746 -2.13974 1.56442 
hsa-miR-141-5p 0.027995 24.48213 37.49911 1.53169 
hsv1-miR-H3 1.45E-04 -4.75690 -3.18933 1.49150 
ebv-miR-BART1-5p 1.09E-05 -33.84535 -24.5516 1.37854 
hcmv-miR-UL70-3p 0.001715 -2.77372 -2.01710 1.37501 
hsa-miR-670 5.30E-04 -11.33349 -8.45322 1.34073 
hsa-miR-610 5.30E-04 -2.646281 -2.01362 1.31419 
hsa-miR-139-3p 0.002508 -2.791654 -2.13508 1.30751 
hsa-miR-195-3p 2.06E-04 -3.170986 -2.58510 1.22664 
hsa-miR-7-5p 0.043624 6.330076 7.72615 1.22055 
hsa-miR-4279 4.82E-05 -3.101136 -2.70097 1.14816 
hsv2-miR-H7-3p 1.45E-04 -2.313273 -2.02378 1.14304 
ebv-miR-BART11-3p 4.82E-05 -2.980643 -2.61500 1.13982 
hsa-miR-605 0.001945 -2.701080 -2.41566 1.11815 
hsv1-miR-H1 0.002834 -2.904213 -2.61325 1.11134 
hsa-miR-1915-5p 5.30E-04 -2.852665 -2.56942 1.11024 
hsa-miR-125b-2-3p 0.002592 -2.216214 -2.00739 1.10402 
hsa-miR-551b-5p 5.53E-04 -2.957645 -2.71326 1.09007 
hsa-miR-1909-5p 0.01109 -2.187650 -2.01615 1.08506 
hsa-miR-29b-3p 0.023843 3.098345 3.36130 1.08487 
hsa-miR-454-3p 0.002592 2.045415 2.20069 1.07592 
hsa-miR-3155a 1.46E-04 -2.152257 -2.01079 1.07035 
hsa-miR-132-3p 0.00401 2.678988 2.85432 1.06545 
kshv-miR-K12-12 0.020011 -2.531076 -2.46680 1.02606 
hsa-miR-181a-5p 0.029224 2.180832 2.22445 1.02000 
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hsa-miR-3151 5.30E-04 -2.134066 -2.09751 1.01742 
hsa-miR-93-5p 0.041808 2.233950 2.17524 -1.02699 
hiv1-miR-H1 0.044691 -2.210104 -2.30172 -1.04146 
hsa-miR-4317 0.026188 2.105246 2.01773 -1.04337 
hsa-miR-27a-3p 0.043624 2.826095 2.69947 -1.04690 
hsa-miR-141-3p 0.013427 10.81161 10.23016 -1.05684 
hsa-miR-21-5p 0.020011 3.79329 3.56598 -1.06374 
hsa-miR-331-3p 0.002612 3.12259 2.87675 -1.08546 
hsa-miR-23a-3p 0.041377 3.13897 2.81030 -1.11695 
hsa-miR-3065-5p 0.012487 -2.18501 -2.45883 -1.12532 
hsa-miR-4267 0.004431 -2.03989 -2.33321 -1.14380 
hsa-miR-200c-3p 0.018654 11.08151 9.62122 -1.15178 
hsa-miR-146b-5p 0.012487 4.02472 3.46128 -1.16278 
hsa-miR-106b-5p 0.029224 2.88392 2.45642 -1.17403 
hsa-miR-210 0.014745 4.13911 3.39742 -1.21831 
hsa-miR-425-5p 0.012487 3.40384 2.76990 -1.22887 
hsa-miR-222-3p 0.004354 5.95207 4.82987 -1.23234 
hsa-miR-221-3p 0.003211 5.83729 4.68405 -1.24620 
hsa-miR-135b-5p 0.020011 30.41217 22.75650 -1.33642 
hsa-miR-665 0.034674 -2.04905 -2.75661 -1.34531 
hsa-miR-223-3p 0.011902 5.21594 3.65900 -1.42550 
hsa-miR-1273c 0.011902 -2.04719 -3.03805 -1.48401 
hsv1-miR-H8* 0.023843 -2.12146 -3.40951 -1.60716 
hsa-miR-183-5p 0.03395 7.25323 4.29224 -1.68985 
hsa-miR-132-5p 0.020011 26.20608 15.16595 -1.72795 
hsa-miR-31-5p 1.09E-05 117.31276 60.36202 -1.94349 
hsa-miR-3152-3p 0.01109 -8.38224 -16.99140 -2.02710 
hsa-miR-182-5p 0.023843 49.70194 20.06405 -2.47716 
hsa-miR-221-5p 0.012907 76.10488 30.66719 -2.48163 
hsa-miR-31-3p 1.09E-05 1992.38980 742.40680 -2.68369 
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FIGURES 
Fig. 1. Representative images of CTT, D-NT, and N-NT FFPE tissue. Panel A: normal liver 
with mild macrovesicular steatosis (arrowhead) and portal triad (arrows), H&E (20X). Panel B; a 
trichrome stain shows no significant pericentral fibrosis; a normal amount of periportal fibrous 
tissue is present (arrow) H&E (2X).  Panel C: well differentiated cholangiocarcinoma as shown 
by angulated glands with luminal mucin (long arrow) and cytologic atypia (short arrow) in a 
dense fibrous stroma, H&E (20X). Panel D: moderately differentiated cholangiocarcinoma, with 
malignant cribriform glands involving a nerve (short arrow) and a lymphatic space (arrowhead), 
H&E (10X). Panel E: invasive component of papillary adenocarcinoma composed of angulated 
glands with luminal mucin, H&E (20X); Panel F: invasive papillary adenocarcinoma (arrow) and 
interface with adjacent normal liver (*), H&E (10X). 
Fig. 2. Hierarchical Analysis and clustering of FFPE cholangiocarcinoma and healthy 
liver samples by microarray. (A) Healthy liver samples (N-NT) show a hierarchical profile 
clustered together (Red), while tumor (CTT) (Grey) and distal apparently normal tissue 
macrodissected distant from dysplasia or frank cancer (D-NT) (Blue) show some diversity, but 
clustered closely with (CTT). The >1600 human miRNAs are also hierarchical grouped (Left) 
and expression exhibited on a heatmap. (B) PCA 3D clustering of cholangiocarcinoma and 
healthy liver FFPE cohorts. (N-NT) tissue from non-CCA cases cluster together, while tissue 
samples from CCA cases showed diversity in overall scoring. 
Fig. 3. Histological bias of miRNA analysis from microarray.  miRNAs were analyzed by two 
methods according to histology: (A) Distal tissue from the same CCA patient (D-NT) compared 
to CCA tumor tissue (CTT) and (B) CTT compared against non-tumor samples biopsied from of 
individuals undergoing gastric bypass surgery (N-NT). miRNAs that exhibited (A) FC ≥ 2, p ≤ 
0.05, and raw values >30 via a paired test, and (B) FC ≥ 2, p ≤ 0.05, raw values > 30 via 
unpaired T test, were used in the comparison lists.  
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Fig. 4. miRNA Fold Changes between CCA histological classifications by qPCR. Six 
miRNAs (hsa-mir: -135b, -141, -200c, -21, -221, -222) identified by microarray were verified by 
qPCR in the same CTT, N-NT and D-NT(not shown) samples. The qPCR results were also 
compared to fold changes determined by microarray (Supplemental Figure 1). Error bars 
represent 95% confidence interval, and asterisks denote p-value: (*) p ≤ 0.05 and (**) p ≤ 0.01, 
(***) p ≤ 0.001. 
SUPPLEMENTAL FIGURES 
Supplementary Fig. S1. miRNA Fold Changes between qPCR and Microarray by CCA 
histological classifications. Fold changes of six miRNAs (hsa-mir: -135b, -141, -200c, -21, -
221, -222) verified by qPCR and compared to values determined during microarray analysis of 
the same samples.  
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